⌘K
Loading ticker…
Celldex Therapeutics, Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, Celldex Therapeutics, Inc (CLDX) has a 3-month relative strength percentile of 59 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 59. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.0%, relative volume 4.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
59 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CLDX is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 9.9% / 24.7%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CLDX is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $68M notional. Top 3 carry $158M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $68M |
| IWMiShares Russell 2000 ETF | 0.07% | $51M |
| XBIState Street SPDR S&P Biotech ETF | 0.52% | $39M |
| VXFVanguard Extended Market ETF | 0.03% | $24M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLDX Jan avg: -6.21% median: -6.26% win: 0% σ: 4.85% n: 4 2022-04-12 → 2026-05-29 | CLDX Feb avg: 9.97% median: 9.72% win: 50% σ: 23.76% n: 4 2022-04-12 → 2026-05-29 | CLDX Mar avg: -8.73% median: -12.22% win: 25% σ: 9.60% n: 4 2022-04-12 → 2026-05-29 | CLDX Apr avg: -3.13% median: -10.62% win: 40% σ: 11.96% n: 5 2022-04-12 → 2026-05-29 | CLDX May avg: -8.46% median: -5.04% win: 20% σ: 9.20% n: 5 2022-04-12 → 2026-05-29 | CLDX Jun avg: 8.84% median: 8.92% win: 100% σ: 5.13% n: 4 2022-04-12 → 2026-05-29 (current) | CLDX Jul avg: 7.29% median: 6.11% win: 100% σ: 4.93% n: 4 2022-04-12 → 2026-05-29 | CLDX Aug avg: -3.31% median: -0.29% win: 50% σ: 12.57% n: 4 2022-04-12 → 2026-05-29 | CLDX Sep avg: -2.37% median: -4.45% win: 25% σ: 14.68% n: 4 2022-04-12 → 2026-05-29 | CLDX Oct avg: -2.39% median: -5.61% win: 50% σ: 21.35% n: 4 2022-04-12 → 2026-05-29 | CLDX Nov avg: 10.10% median: 5.44% win: 100% σ: 12.40% n: 4 2022-04-12 → 2026-05-29 | CLDX Dec avg: 11.02% median: 10.34% win: 75% σ: 17.91% n: 4 2022-04-12 → 2026-05-29 |